VANCOUVER, BC — October 30, 2025 — Leads & Copy — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) has increased its non-brokered private placement financing to a minimum of 10,588,235 units at $0.17 per unit, aiming to raise $1,800,000, and up to a maximum of 11,764,705 units for gross proceeds of up to $2,000,000.
Each unit includes one common share and one common share purchase warrant, allowing the holder to acquire an additional share at $0.40 for 24 months from issuance.
The offering, expected to close by November 10, 2025, is subject to regulatory approvals. Proceeds will support licensing opportunities, research collaborations, supply and production of DPX, initiation of a food allergy program at McMaster University, patent filings, and immunological data analysis from MVP-S phase 1 studies.
Units are offered for sale under the listed issuer financing exemption in Canadian provinces (excluding Quebec) and other qualifying jurisdictions. Securities issued are not subject to a hold period under Canadian securities laws.
An amended offering document is available on SEDAR+ and BioVaxys’ website.
The securities have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States except in compliance with registration requirements or available exemptions.
James Passin, Chief Executive Officer
Phone: +1 740 358 0555
Source: BioVaxys Technology Corp.
